0001354488-11-003198.txt : 20110901 0001354488-11-003198.hdr.sgml : 20110901 20110901171327 ACCESSION NUMBER: 0001354488-11-003198 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110901 ITEM INFORMATION: Termination of a Material Definitive Agreement FILED AS OF DATE: 20110901 DATE AS OF CHANGE: 20110901 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC CENTRAL INDEX KEY: 0000834365 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943076866 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-18170 FILM NUMBER: 111071682 BUSINESS ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4254011400 MAIL ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: BIOLIFE SOLUTION INC DATE OF NAME CHANGE: 20030113 FORMER COMPANY: FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC DATE OF NAME CHANGE: 19920703 8-K 1 blfs_8k.htm CURRENT REPORT blfs_8k.htm
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549
______________________________

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

September 1, 2011
Date of report (Date of earliest event reported)
____________________________________

BIOLIFE SOLUTIONS, INC.
(Exact Name of Registrant as Specified in Charter)
 
Delaware     0-18710     94-3076866
(State or Other Jurisdiction of Incorporation)     (Commission File No.)      (IRS Employer Identification No.)
         
 
3303 Monte Villa Parkway, Bothell, WA 98021
(Address of principal executive offices, including zip code)

(425) 402-1400
(Registrant’s telephone number, including area code)
____________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


 
 
 
 
 
 
ITEM 1.02  Termination of a Material Definitive Agreement

On August 29, 2011, BioLife Solutions, Inc., (the “Company”) and Roderick de Greef, a director of the Company who has been consulting to the Company by providing oversight over the Company’s financing activities, internal accounting functions and SEC reporting, and assisting in the search for, and reviewing of strategic alternatives, agreed to terminate the Consulting Agreement, dated November 15, 2007, between the Company and Mr. de Greef, effective 90 days from the date of notification.  Mr. de Greef has waived his right to receive any compensation under the Consulting Agreement during the 90 period pending the effectiveness of the termination of the Consulting Agreement. The agreement was terminated in relation to the appointment of Daphne Taylor by the Board of Directors to the position of Vice President, Finance and Administration and Chief Financial Officer on August 17, 2011. Mr. de Greef retains his membership on the Board of Directors of the Company.
  
 The Consulting Agreement was terminable by either party, without liability, upon 90 days prior written notice.
  
 The preceding summary of the Consulting Agreement does not purport to be complete and is subject to the full text of the Consulting Agreement, a copy of which was originally filed as an exhibit to our Annual Report on Form 10-K for the year ended December 31, 2007.
 
 
 
2
 


Signatures:

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date:  September 1, 2011

 
BIOLIFE SOLUTIONS, INC.
  
       
 
By:
/s/ Daphne Taylor   
    Daphne Taylor  
   
Chief Financial Officer
  
       
 


3